Special Issue

Mesenchymal Stem Cell-Derived Extracellular Vesicles as Therapeutics

Message from the Guest Editors

Mesenchymal stromal cells (MSCs) have gained attention in the field of regenerative medicine. MSCs' differentiation potential together with their paracrine properties has made them a crucial option for tissue healing. MSCs' paracrine properties rely on the release of soluble factors and extracellular vesicles (EVs) such as exosomes and microvesicles. In the last decade, EVs have been postulated as crucial players for the therapeutic effect of MSCs in several in vitro and in vivo disease models. Moreover, a number of clinical trials using MSC-EVs have been started covering cancer. neurological diseases and diabetes. Hence, MSC-EVs may be envisioned as a cell-free therapy in regenerative medicine and all those diseases where tissue healing is needed. Nevertheless, a deep characterization of the cargo fingerprint associated with the MSC source and an explanation of MSCs' properties are still largely missing. Therefore, the aim of this Special Issue is to collect reports from in vitro to clinical trials aimed at shedding light on MSC-EV features at both the physiological and molecular levels.

Guest Editors

Dr. Enrico Ragni

Laboratorio di Biotecnologie Applicate All'Ortopedia, IRCCS Ospedale Galeazzi-Sant'Ambrogio, Via Cristina Belgioioso 173, 20157 Milan, Italy

Dr. Carlotta Perucca Orfei

Laboratorio di Biotecnologie Applicate all'Ortopedia, IRCCS Istituto Ortopedico Galeazzi, I-20161 Milano, Italy

Deadline for manuscript submissions

closed (30 June 2022)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 7.9 Indexed in PubMed



mdpi.com/si/101196

Pharmaceutics MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 pharmaceutics@mdpi.com

mdpi.com/journal/ pharmaceutics





an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 7.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).

